cryoprecipitate

Biologicalexperimental

Cryoprecipitate, also called cryo for short, or Cryoprecipitate Antihemophilic factor (AHF), is a frozen blood product prepared from blood plasma. To create cryoprecipitate, plasma is slowly thawed to 1–6 °C. A cold-insoluble precipitate is formed, which is collected by centrifugation, resuspended in a small amount of residual plasma and then re-frozen for storage. Cryoprecipitate contains fibrinogen, Factor VIII, Factor XIII and vWF. In many clinical contexts, use of cryoprecipitate has been replaced with use of clotting factor concentrates, but the whole form is still routinely stocked by many hospital blood banks. Cryo can be stored at −18 °C or colder for 12 months from the original collection date or up to 36 months in Europe if stored below -25 °C. After thawing, single units of cryo can be stored at 20–24 °C for up to 6 hours. If units of cryo are pooled in an open system, they can only be held at 20–24 °C for up to 4 hours. Presently cryo cannot be re-frozen for storage after it is thawed for use if it is not transfused. — Wikipedia

Clinical trial activity

9 trials · 20 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
2

Earliest trial started Jan 31, 2017 (NCT04704869)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cryoprecipitate
  • ffp

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06617897Phase 3Sep 30, 2024CSL Behring
NCT05711524Phase 4Apr 1, 2023Cerus Corporation, Cornell University
NCT05449834Phase 3Oct 1, 2022Australasian College for Emergency Medicine, Australasian Trauma Society, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross, Monash University
NCT04376762Phase 4Sep 1, 2020Octapharma, University of Virginia
NCT03932240Phase 3Jul 31, 2019Emory University
NCT03784794N/ANov 1, 2018Grupo Mexicano para el Estudio de la Medicina Intensiva
NCT03508141Phase 2Jun 1, 2018Australian Red Cross, Emergency Medicine Foundation, Griffith University, Lady Cilento Children's Hospital, National Blood Authority
NCT03045068N/AApr 11, 2017University of Texas at Houston
NCT04704869Phase 3Jan 31, 2017Baylor University, NHS Blood and Transplant, University of London, University of Texas at Houston
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Australian Red CrossAcademic/Hospital2022018
University of Texas at HoustonAcademic/Hospital2222017
Australasian College for Emergency MedicineAcademic/Hospital1012022
Australasian Trauma SocietyAcademic/Hospital1012022
Australian and New Zealand Intensive Care Society Clinical Trials GroupAcademic/Hospital1012022
Baylor UniversityAcademic/Hospital1012017
Cerus CorporationFor profit1012023
Cornell UniversityAcademic/Hospital1112023
CSL BehringFor profit1112024
Emergency Medicine FoundationAcademic/Hospital1012018
Emory UniversityAcademic/Hospital1112019
Griffith UniversityAcademic/Hospital1112018
Grupo Mexicano para el Estudio de la Medicina IntensivaAcademic/Hospital1112018
Lady Cilento Children's HospitalAcademic/Hospital1012018
Monash UniversityAcademic/Hospital1112022
National Blood AuthorityAcademic/Hospital1012018
NHS Blood and TransplantAcademic/Hospital1012017
OctapharmaFor profit1012020
University of LondonAcademic/Hospital1012017
University of VirginiaAcademic/Hospital1112020
20 organizations
Page 1 / 1